CS
NERV icon

Credit Suisse’s Minerva Neurosciences NERV Stock Holding History

Credit Suisse’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,827
Closed -$113K – 4276
2019
Q3 		$113K Sell
1,827
-416
-19% -$23.6K ﹤0.01% 3957
2019
Q2 		$101K Buy
2,243
+231
+11% +$11.6K ﹤0.01% 3949
2019
Q1 		$126K Buy
2,012
+168
+9% +$10.1K ﹤0.01% 3826
2018
Q4 		$100K Buy
+1,844
New +$135K ﹤0.01% 3764
2018
Q3 		– Sell
-2,244
Closed -$149K – 3915
2018
Q2 		$149K Buy
2,244
+476
+27% +$28.9K ﹤0.01% 3801
2018
Q1 		$89K Buy
1,768
+137
+8% +$6.58K ﹤0.01% 3817
2017
Q4 		$79K Sell
1,631
-1,453
-47% -$72K ﹤0.01% 3868
2017
Q3 		$188K Buy
3,084
+1,534
+99% +$88K ﹤0.01% 3948
2017
Q2 		$109K Sell
1,550
-741
-32% -$48K ﹤0.01% 3712
2017
Q1 		$149K Sell
2,291
-1,524
-40% -$118K ﹤0.01% 3658
2016
Q4 		$359K Buy
3,815
+2,131
+127% +$218K ﹤0.01% 3581
2016
Q3 		$190K Buy
+1,684
New +$163K ﹤0.01% 3825

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Credit Suisse's NERV Position: Q4 2019 in Review

Credit Suisse sold out of Minerva Neurosciences (NERV) in Q4 2019, closing a stake of 1,827 shares — an estimated $113K sold.

Credit Suisse first reported a position in NERV in Q3 2016 and held it in 12 quarters. The position peaked at $359K in Q4 2016. 92 funds tracked by Wall St. Rank hold NERV as of Q4 2019.

  • Credit Suisse reported no remaining Minerva Neurosciences position as of Q4 2019 after selling out during the quarter.
  • Credit Suisse sold 1,827 Minerva Neurosciences shares in Q4 2019, an estimated $113K.
  • Credit Suisse first reported a position in Minerva Neurosciences in Q3 2016 and held it in 12 quarters.
  • Credit Suisse's Minerva Neurosciences position peaked at $359K in Q4 2016.
  • 92 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2019.

Based on Credit Suisse's 13F filing for Q4 2019, filed 12 Feb 2020.